UBS AG set a $255.00 price target on Allergan PLC. (NYSE:AGN) in a research report released on Tuesday. The firm currently has a buy rating on the stock.
Several other equities research analysts also recently weighed in on the stock. Credit Suisse Group set a $243.00 target price on shares of Allergan PLC. and gave the company an outperform rating in a research note on Tuesday. J P Morgan Chase & Co restated a buy rating on shares of Allergan PLC. in a research note on Monday. Wells Fargo & Company set a $276.00 target price on shares of Allergan PLC. and gave the company a buy rating in a research note on Friday, October 13th. Piper Jaffray Companies set a $227.00 target price on shares of Allergan PLC. and gave the company a hold rating in a research note on Friday, October 13th. Finally, Cantor Fitzgerald set a $231.00 target price on shares of Allergan PLC. and gave the company a hold rating in a research note on Thursday, October 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $266.69.
Shares of Allergan PLC. (AGN) traded down 4.60% during trading on Tuesday, reaching $188.68. 6,793,654 shares of the company were exchanged. The company’s 50-day moving average is $215.75 and its 200 day moving average is $231.93. The firm has a market capitalization of $63.08 billion, a PE ratio of 5.75 and a beta of 1.15. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. Allergan PLC.’s revenue was up 8.8% compared to the same quarter last year. During the same period last year, the firm earned $3.35 earnings per share. Equities research analysts expect that Allergan PLC. will post $16.20 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/10/18/allergan-plc-agn-given-a-255-00-price-target-at-ubs-ag.html.
Allergan PLC. declared that its board has authorized a share repurchase plan on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Pathstone Family Office LLC increased its holdings in Allergan PLC. by 3,327.3% in the second quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock valued at $2,035,000 after buying an additional 366 shares in the last quarter. Howard Hughes Medical Institute purchased a new position in Allergan PLC. in the second quarter valued at $103,000. Jacobi Capital Management LLC increased its holdings in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares in the last quarter. JNBA Financial Advisors increased its holdings in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares in the last quarter. Finally, Massey Quick & Co. LLC increased its holdings in Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after buying an additional 385 shares in the last quarter. 81.94% of the stock is owned by institutional investors.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.